Sandra Phillips

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial).

Nucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial).

Journal: Hepatology (Baltimore, Md.)
Published: September 19, 2025

The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity.

The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity.

Journal: The lancet. Gastroenterology & hepatology
Published: July 06, 2023

Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing.

Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing.

Journal: EBioMedicine
Published: December 06, 2022

Novel therapeutic strategies for chronic hepatitis B.

Novel therapeutic strategies for chronic hepatitis B.

Journal: Virulence
Published: June 28, 2022

A review of alcohol-pathogen interactions: New insights into combined disease pathomechanisms.

A review of alcohol-pathogen interactions: New insights into combined disease pathomechanisms.

Journal: Alcoholism, clinical and experimental research
Published: November 05, 2021

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.

Journal: Frontiers in immunology
Published: March 16, 2017

Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption.

Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption.

Journal: Viral immunology
Published: May 07, 2014

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.

Journal: Gastroenterology
Published: December 15, 2013
Showing 1-8 of 8

Last Updated: 09/26/2026